Brief: Lantern Pharma Completes Targeted Enrollment For Lung Cancer Phase 2 Harmonic™ Clinical Trial In Japan For LP-300
31/07/2025 13:10
July 31 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA COMPLETES TARGETED ENROLLMENT FOR LUNG CANCER PHASE 2 HARMONIC™ CLINICAL TRIAL IN JAPAN FOR LP-300 Source text: ID:nBw8Q2sBFa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview